PROM1 and cancer: Given the observed divergent expression of SSEA-4 and CD133-two critical markers associated with cancer progression and chemoresistance-we conducted an analysis of the dose-response survival rates of the CM sublines compared to their parental lines, 48 hours after treatment with CPT.